针对性纳米载体用于系统输送IRAK4抑制剂到炎症组织
Youngrong Park1,2, Tetiana Korzun1,3, Abraham S Moses1
1Department of Pharmaceutical Sciences, College of Pharmacy, Oregon State University, 2730 S Moody Avenue, Portland, Oregon, 97201, USA.
Small (Weinheim an der Bergstrasse, Germany)
|September 13, 2023
概括
向的纳米颗粒有效地将IRAK4抑制剂传递给炎症组织,显著减少炎症及其症状. 这种新的药物输送系统显示出治疗炎症疾病而没有急性毒性的前景.
科学领域:
- 生物医学工程 生物医学工程
- 药物输送系统 药物输送系统
- 免疫学 免疫学 免疫学
背景情况:
- 持续的炎症导致许多疾病.
- 介素-1受体相关激酶4 (IRAK4) 是一个关键的炎症调节剂.
- 针对性地提供IRAK4抑制剂对于有效治疗至关重要.
研究的目的:
- 开发第一个纳米粒子平台,以有针对性地提供IRAK4抑制剂PF-06650833.
- 提高药物在炎症组织中的水分分散性和向积累.
- 在临床前模型中评估纳米载体系统的治疗疗效和安全性.
主要方法:
- 基于纳米颗粒的药物输送系统的制定,用于PF-06650833.
- 在纳米载体表面上加入向性.
- 通过静脉注射评估纳米载体在炎症组织中的积累 (脚胀,小鼠的性结肠炎模型).
- 对抗炎症作用的评估和对器官毒性的评估.
主要成果:
- 纳米载体增加了PF-06650833的水 dispersibility 的40倍.
- 与非向的纳米载体相比,向的纳米载体在炎症组织中增加了积累.
- 治疗减少了脚胀,大肠炎症状和促炎性细胞因子水平.
- 经过多次注射,主要器官没有出现急性毒性.
结论:
- 开发的纳米载体平台使IRAK4抑制剂的向输送成为可能.
- 这种系统显著提高了炎症状况的治疗疗效.
- 纳米载体为管理炎症性疾病提供了一个有前途的战略.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
168
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
168
Inflammatory Bowel Disease IV: Pharmacological Management
152
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
152
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
190
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
190


